PONIARD PHARMACEUTICALS, INC. KEY EXECUTIVE SEVERANCE AGREEMENTKey Executive Severance Agreement • February 11th, 2010 • Poniard Pharmaceuticals, Inc. • Pharmaceutical preparations
This Key Executive Severance Agreement (this “Agreement”), dated as of February 5, 2010, is entered into by and between PONIARD PHARMACEUTICALS, INC., a Washington corporation (as supplemented by Section 10 hereof, the “Company”), and Michael S. Perry, DVM, Ph.D. (the “Executive”).
1 Exhibit 10.34 KEY EXECUTIVE SEVERANCE AGREEMENT This Key Executive Severance Agreement (the "Agreement") is dated as of September 4, 1996, and is made by and between Dove Audio, Inc., a California corporation (the "Company"), and Gerald Leider who...Key Executive Severance Agreement • May 20th, 1997 • Dove Entertainment Inc • Phonograph records & prerecorded audio tapes & disks • California
KEY EXECUTIVE SEVERANCE AGREEMENT THIS AGREEMENT, made and entered into as of the 31st day of January, 2002, by and between FRESH BRANDS, INC., a Wisconsin corporation (the "Company"), and WALTER G. WINDING (the "Executive"). W I T N E S S E T H :...Key Executive Severance Agreement • March 15th, 2002 • Fresh Brands Inc • Retail-grocery stores • Wisconsin
KEY EXECUTIVE SEVERANCE AGREEMENTKey Executive Severance Agreement • January 27th, 2017 • Ducommun Inc /De/ • Aircraft parts & auxiliary equipment, nec • California
This Key Executive Severance Agreement (the “Agreement”) is dated as of [date], and is made by and between Ducommun Incorporated, a Delaware corporation (the “Company”), and [name] who is presently [position] of the Company (the “Executive”).
WITNESSETH:Key Executive Severance Agreement • April 14th, 2000 • Newstar Media Inc • Phonograph records & prerecorded audio tapes & disks • California
AMENDMENT NO. 1 TO AMENDED AND RESTATED KEY EXECUTIVE SEVERANCE AGREEMENTKey Executive Severance Agreement • February 11th, 2010 • Poniard Pharmaceuticals, Inc. • Pharmaceutical preparations
This Amendment No. 1 (this “Amendment”), dated as of February 5, 2010, is entered into by and between PONIARD PHARMACEUTICALS, INC., a Washington corporation (the “Company”), and RONALD A. MARTELL (the “Executive”).
KEY EXECUTIVE SEVERANCE AGREEMENTKey Executive Severance Agreement • January 3rd, 2008 • Ducommun Inc /De/ • Aircraft parts & auxiliary equipment, nec • California
This Key Executive Severance Agreement (the “Agreement”) is dated as of [date], and is made by and between Ducommun Incorporated, a Delaware corporation (the “Company”), and [name], who is presently [position] of the Company (the “Executive”).
AMENDMENT NO. 1 TO NEORX CORPORATION KEY EXECUTIVE SEVERANCE AGREEMENTKey Executive Severance Agreement • May 10th, 2005 • Neorx Corp • In vitro & in vivo diagnostic substances
This Amendment, dated as of March 30, 2005, is entered into by and between NEORX CORPORATION (the “Company”) and LINDA FINDLAY (the “Executive”) with respect to the Key Executive Severance Agreement between the Company and the Executive dated as of February 28, 2003 (the “Agreement”) as follows:
AMENDMENT NO. 1 TO NEORX CORPORATION KEY EXECUTIVE SEVERANCE AGREEMENTKey Executive Severance Agreement • May 10th, 2005 • Neorx Corp • In vitro & in vivo diagnostic substances
This Amendment, dated as of March 30, 2005, is entered into by and between NEORX CORPORATION (the “Company”) and ANNA WIGHT (the “Executive”) with respect to the Key Executive Severance Agreement between the Company and the Executive dated as of February 28, 2003 (the “Agreement”) as follows:
AMENDMENT NO. 1 TO NEORX CORPORATION KEY EXECUTIVE SEVERANCE AGREEMENTKey Executive Severance Agreement • May 10th, 2005 • Neorx Corp • In vitro & in vivo diagnostic substances
This Amendment, dated as of March 30, 2005, is entered into by and between NEORX CORPORATION (the “Company”) and KAREN AUDITORE-HARGREAVES (the “Executive”) with respect to the Key Executive Severance Agreement between the Company and the Executive dated as of May 13, 2003 (the “Agreement”) as follows:
AMENDMENT NO. 1 TOKey Executive Severance Agreement • May 10th, 2005 • Neorx Corp • In vitro & in vivo diagnostic substances
This Amendment, dated as of March 30, 2005, is entered into by and between NEORX CORPORATION (the “Company”) and SUSAN D. BERLAND (the “Executive”) with respect to the Key Executive Severance Agreement between the Company and the Executive dated as of October 25, 2004 (the “Agreement”) as follows:
